These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 28275823

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
    Kühne T, Imbach P.
    Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
    [Abstract] [Full Text] [Related]

  • 4. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ.
    Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
    [Abstract] [Full Text] [Related]

  • 5. Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics.
    Gebetsberger J, Streif W, Dame C.
    Hamostaseologie; 2024 Aug; 44(4):316-325. PubMed ID: 38925157
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.
    Červinek L, Mayer J, Doubek M.
    Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis.
    Tumaini Massaro J, Chen Y, Ke Z.
    Platelets; 2019 Jul; 30(7):828-835. PubMed ID: 30810479
    [Abstract] [Full Text] [Related]

  • 12. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T, Harada Y, Matsubara E, Suzuki T, Oyama T, Kasai M, Uchida T, Ogura M.
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.
    Lam MS.
    J Oncol Pharm Pract; 2010 Jun; 16(2):89-103. PubMed ID: 19525300
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A Review of Romiplostim Mechanism of Action and Clinical Applicability.
    Bussel JB, Soff G, Balduzzi A, Cooper N, Lawrence T, Semple JW.
    Drug Des Devel Ther; 2021 Jun; 15():2243-2268. PubMed ID: 34079225
    [Abstract] [Full Text] [Related]

  • 20. Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia.
    Qu MM, Liu XN, Liu XG, Feng Q, Liu Y, Zhang X, Liu S, Zhang L, Li GS, Zhu YY, Lv MY, Peng J, Hou M.
    Cytokine; 2017 Apr; 92():110-117. PubMed ID: 28142109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.